(I) CTG-Industry Collaborative Trials (CTG-ICT) scheme
Description
This scheme supports ICTs that involve both clinician and company contributing intellectual inputs and funds to conduct the trial and developing novel or pre-existing therapies/drugs/medical device for new indications.
This scheme does not support trials that are fully funded/sponsored by companies. Such trials typically do not require the clinicians’ intellectual inputs as the clinical trial protocol has already been designed by the company, and the clinicians’ involvement is more for subject/patient recruitment.
NEW (1 Nov 2019 onwards): Pls note that CTG-ICT will have a focus on early phase trials
Prerequisites
The prerequisite for application is PI’s ability to obtain industry contribution of at least 70% (cash or in-kind) of the Total Project Costs (TPC). The TPC and industry contribution will be based on the Research Collaborative Agreement (RCA) between the host institution (HI) and the industry partner.
- In IGMS, pls ensure that:
(i) the industry contribution is clearly indicated in Section 3 of the proposal in the application form and
(ii) the RCA is uploaded in the “Other Attachments" section/tab. The RCA should clearly indicate the budget information (PI and industry contribution, and the TPC as reflected in the proposal).
- Pls note that:
(i) the admissible in-kind drug cost contribution from the industry partner is limited to equivalent to the non-drug cost contribution (pls refer to slide 16 of NMRC May 2018 Grant Call Roadshow slides for an example of the calculation).
(ii) If the project is awarded, the PI/HI will be required to:
- ensure that the industry contribution is met at the completion of the awarded project.
- submit yearly reporting on the industry contribution (Refer to the “Guidelines for Annual Reporting of Industry Contributions” to complete “Industry Contribution Form” with supporting documents e.g. receipts, invoices), together with the annual progress report.
Industry Contribution Form
Guidelines for the Annual Reporting of Industry Contributions
Funding Quantum and duration
The scheme will cover up to 30% of the TPC inclusive of 20% indirect costs.
Funding quantum for each project is open and for a duration of up to 5 years.
Review Process
All applications will undergo a streamlined review process and the assessment criteria include the following:
- Scientific and clinical merit of proposal
- Track record of applicants
- Focus on HBMS 5 priority therapeutic areas and early phase trials (1 Nov 2019 onwards)
- Address unmet clinical need in SG with good potential to be implemented in local healthcare system
- Agreement with industry partner on IP
- Result in technology transfer, talent and/or capability building which SG would like to gain (or strengthen SG’s position in points 3 and 4)
- Lead to some form of return on investment for SG (e.g. healthcare savings, discounted price for use of therapy, royalties, further contribution to research activities etc
The review process will take about 2 months after application endorsement by HI.
Grant Call Frequency/Submission
Please note that the CTG-ICT has closed on 13 Nov 2020 for the RIE 2020 tranche.